EMEA-001072-PIP01-10-M04
Key facts
Invented name |
Lemtrada
|
Active substance |
alemtuzumab
|
Therapeutic area |
Neurology
|
Decision number |
P/0269/2020
|
PIP number |
EMEA-001072-PIP01-10-M04
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of multiple sclerosis
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Genzyme Europe B.V.
Tel: +49 (0) 800 52 52 010 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|